Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Extragonadal germ cell tumour, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cure rates for mediastinal non-seminoma remain well below those of testicular primaries.
The role of high-dose chemotherapy in first-line poor-risk disease is still being tested (TIGER trial).
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
The Alliance and European groups randomise first-relapse germ cell tumours between conventional-dose TIP and high-dose TI-CE with stem cell rescue, the first randomised test of high-dose salvage since the 1990s.
Bokemeyer and colleagues pool 635 patients from eleven centres: seminomas do as well as testicular disease, mediastinal non-seminomas do worst, and prognostic factors are defined.
The International Germ Cell Cancer Collaborative Group defined good, intermediate and poor risk; a mediastinal non-seminomatous primary alone places a patient in the poor-risk group.
Etoposide in place of vinblastine gave equal cure with less neurotoxicity in the Indiana and SECSG trials.
Einhorn's PVB regimen (cisplatin, vinblastine, bleomycin) turned a usually fatal cancer into a curable one.